Full text
Earnings transcript
Read the complete earnings call transcript.
ABBV
AbbVie Inc.
$216.63
-4.6
(-2.08%)
| Exchange: | NYSE |
| Market Cap: | 382.74B |
| Shares Outstanding: | 1.616B |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Robert A. Michael | |||||
| Full Time Employees: | 55000 | |||||
| Address: |
| |||||
| Website: | https://www.abbvie.com |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet’s diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women’s Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson’s disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 54,318,000 | 56,334,000 | 61,160,000 |
| Gross Profit | 33,903,000 | 39,430,000 | 42,956,000 |
| EBITDA | 17,172,000 | 14,910,000 | 17,629,000 |
| Operating Income | 12,757,000 | 9,137,000 | 20,091,000 |
| Net Income | 4,863,000 | 4,278,000 | 4,226,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 134,711,000 | 135,161,000 | 0 |
| Total Liabilities | 124,314,000 | 131,797,000 | 2,599,000 |
| Total Stockholders Equity | 10,360,000 | 3,325,000 | -2,599,000 |
| Total Debt | 60,120,000 | 67,841,000 | 0 |
| Cash and Cash Equivalents | 12,814,000 | 5,524,000 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 22,839,000 | 18,806,000 | 0 |
| Capital Expenditure | -777,000 | -974,000 | 0 |
| Free Cash Flow | 22,062,000 | 17,832,000 | 0 |
| Net Income | 4,820,000 | 4,286,000 | 4,226,000 |
| Net Change in Cash | 3,613,000 | -7,290,000 | -5,524,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 82,013,904.172 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 84,885,142.157 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 83,729,451.098 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 28,070,667.911 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 29,053,398.447 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 28,657,843.324 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 34,718,404.079 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 36,308,493.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 35,668,469.780 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 19,855,835.331 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 20,550,971.469 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 20,271,174.871 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 20.110 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 20.470 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 19.570 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 12 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: AbbVie reported impressive results in its Q2 2025 earnings call, with strong revenue and net income growth, driven by key product categories as highlighted in the earnings summary. This performance aligns with positive historical trends in income statements, showcasing consistent operating income and EPS growth.
- Strong Cash Flow Generation: Free cash flow yield (as per key metrics TTM) remains solid, supported by significant net cash provided by operating activities in recent cash flow statements. This provides financial flexibility for dividends, debt management, and reinvestment in innovation.
- Market Leadership in Key Segments: AbbVie’s revenue product segments demonstrate dominance in core therapeutic areas, contributing to a high gross profit margin (TTM data). The company’s strategic focus on high-growth products underpins its competitive positioning within the pharmaceutical industry.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates ABBV intrinsic value between $98.00 – $147.99 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about ABBV valuation
Is AbbVie Inc. (ABBV) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for AbbVie Inc. (ABBV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ABBV a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ABBV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ABBV’s P/E ratio?
You can see ABBV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ABBV?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ABBV a good long-term investment?
Whether ABBV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ABBV
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-2.08
Trading Metrics:
| Open: | 221.37 | Previous Close: | 221.23 | |
| Day Low: | 215.37 | Day High: | 222.35 | |
| Year Low: | 181.73 | Year High: | 244.81 | |
| Price Avg 50: | 211.67 | Price Avg 200: | 220.54 | |
| Volume: | 5.076M | Average Volume: | 6.423M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeABBV full analysis
Hey everyone, welcome back to the channel. Today, we’re taking a deep dive into AbbVie, ticker ABBV. This is a name that’s been on a lot of radars lately, especially after that 12% jump in a month. But is this just a dead cat bounce, or is there real substance behind the move? We're going to break down the business, the numbers, the pipeline, and what the future really looks like for this pharma giant. Let’s get into it. AbbVie…
